March 2, 2021
Business News

Metrion Biosciences and LifeArc Further Extend Neuroscience-focused Ion Channel Drug Discovery Collaboration


CAMBRIDGE, England & LONDON–()–Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical research charity, today announced a 12-month extension of their neuroscience drug discovery collaboration, as a result of the continued success of their ongoing agreement.

The collaboration is focused on the discovery of novel selective small molecular modulators of a specific two-pore domain potassium ion channel target, identified as likely to be involved in neurological pathogenesis, and has now progressed into the hit-to-lead optimisation phase. Initially signed in January 2019, the collaboration agreement was extended for the first…



Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
Massachusetts Innovation Network Announces Inaugural Global Innovation Showcase
Topcon Partnership with CyArk Bolsters Cultural Site Archival Efforts
Cipla Gulf and Alvotech Expand Partnership for Commercialization of Biosimilars in Australia and New Zealand